Kymera Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kymera Therapeutics (KYMR).

Price Target Range — 12 Quarters

Analyst Consensus — 25 Analysts

22Buy

3Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$116Upside to Avg. PT-1.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Morgan Stanley	James Quigley	PT Raise	Overweight	$135→$146
Oct 9, 2026	Raymond James	Thomas Deal	Initiate	Outperform	$140
Oct 5, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$135→$150
Sep 22, 2026	Stifel	Alex Thompson	PT Raise	Buy	$132→$152
Sep 14, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$123→$144
Sep 10, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	—
Aug 31, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$135→$170
Aug 27, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$116→$151
Aug 6, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$133→$139
Jul 30, 2026	Deutsche Bank	David Hoang	Initiate	Hold	$120
Jul 28, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$125→$135
Jul 16, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$120→$140
Jul 13, 2026	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$106→$115
Jun 30, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$110→$125
Jun 29, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$116→$136
Jun 29, 2026	B. Riley Securities	Kalpit Patel	PT Raise	Buy	$117→$155
Jun 26, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$106→$129
Jun 25, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$134
May 6, 2026	Canaccord Genuity	Edward Nash	Initiate	Buy	$106
Mar 16, 2026	Jefferies	Faisal Khurshid	Assumes	Buy	$122→$110

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $135 to $146.

Benzinga Newsdesk

This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiate coverage: Outperform on American Express and Kymera, Overweight on Kratos, Hold on IBM and Neutral on Duos.

Avi Kapoor

PRO
Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140

Raymond James analyst Thomas Deal initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $140.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150

Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $150.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

Stifel analyst Alex Thompson maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $132 to $152.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $123 to $144.

Benzinga Newsdesk

Kymera Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Kymera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140

PRO
Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150

PRO
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

PRO
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

People Also Watch

People Also Watch

Kymera Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Kymera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRORaymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140

PROCitigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150

PROStifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

PROB of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

PRO
Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140

PRO
Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150

PRO
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

PRO
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144